Neurocrine Biosciences | NBIX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Acadia Pharmaceuticals USD 279.64M 36.37M 2026-06
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
ALKERMES USD 375.31M 43.98M 2026-06
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amgen USD 5.87B 1.02B 2026-03
Biogen USD 2.12B 307M 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Cytokinetics USD 23.03M 3.84M 2026-06
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Exelixis USD 608.03M 17.17M 2026-06
Gilead Sciences USD 6.8B 1.29B 2026-06
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Incyte USD 1.57B 400.89M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Pfizer USD -248M 11.29B 2026-06
Prothena USD 51.08M 51.06M 2026-03
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Repligen USD 110.04M 1.75M 2026-06
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Teva Pharmaceutical Industries USD 2.15B 45M 2026-06
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06